TODAY’S PAPER | September 28, 2025 | EPAPER

Halsey shares chemotherapy update for rare disorder while preparing for Back to Badlands tour

Halsey revealed she is undergoing chemotherapy for a rare disorder while rehearsing for her upcoming tour.


Pop Culture & Art September 27, 2025 1 min read
Photo: AFP

Halsey has shared a health update with fans, confirming she is undergoing chemotherapy for a rare disorder while also preparing for her upcoming tour.

In a TikTok video posted on September 25, the singer explained: “Just coming on here to give you guys a speed round of updates.

Just did another few sessions of chemo, had a new port placed.” Medical tape could be seen across her collarbone and chest in the clip.

Halsey first disclosed in 2024 that she had been diagnosed with lupus and a rare T-cell lymphoproliferative disorder, a condition linked to an overproduction of white blood cells. Chemotherapy is a common treatment for such disorders.

When a fan, whose husband was receiving similar treatment, asked how she coped, Halsey replied: “I also can’t stand for like a week or more. You guys see me between treatment where I have energy. The time flies by when I’m recovering so it doesn’t seem like as long, but it’s definitely a while.”

She added: “Shout out to your hubby for being a badass and sharing duel diagnosis with me! Much love to both of you!”

Alongside her health journey, Halsey is preparing for her Back to Badlands tour. She said: “We just put the Back to Badlands show together, and it’s going to be unbelievable. We start rehearsals very, very soon, and I’m so excited. I am playing the entire album, plus bunch of other extra fun ones.”

The singer, who shares a son with ex-partner Alev Aydin, became engaged to actor Avan Jogia in September 2024.

Speaking previously on Call Her Daddy, she praised Jogia’s support, saying: “There’s no conversation we can’t have. He’s so solution-oriented.”

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ